The investigators will evaluate in Part A, nivolumab combined with daratumumab with or without lenalidomide-dexamethasone (total 40 patients). Based on efficacy and tolerability, the investigators will treat in Part B 20 additional patients with nivolumab combined with daratumumab either with or without lenalidomide-dexamethasone based on tolerability and efficacy data obtained in Part A.